home / stock / rhhvf / rhhvf news


RHHVF News and Press, Roche Holding Div Rts From 04/26/24

Stock Information

Company Name: Roche Holding Div Rts
Stock Symbol: RHHVF
Market: OTC
Website: roche.com

Menu

RHHVF RHHVF Quote RHHVF Short RHHVF News RHHVF Articles RHHVF Message Board
Get RHHVF Alerts

News, Short Squeeze, Breakout and More Instantly...

RHHVF - AbbVie's Q1: Positive Surprise

2024-04-26 12:01:50 ET Summary AbbVie's Q1 earnings beat estimates, with a smaller decline in Humira sales than expected. The company's next-generation drugs, Rinvoq and Skyrizi, are offsetting the decline in Humira sales. AbbVie's profitability will be weaker than in previous...

RHHVF - These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

RHHVF - Roche Holding AG (RHHBY) Q1 2024 Sales/Trading Statement Call Transcript

2024-04-24 16:16:00 ET Roche Holding AG (RHHBY) Q1 2024 Sales/ Trading Statement Conference Call April 24, 2024 08:00 AM ET Company Participants Thomas Schinecker - Chief Executive Officer, Roche Group Alan Hippe - Chief Financial & Information Officer Teresa...

RHHVF - Artisan International Fund Q1 2024 Commentary

2024-04-24 10:00:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio meaningfully beat the benchmark MSCI EAFE Index, as well as the seconda...

RHHVF - Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

2024-04-17 13:26:56 ET Summary Tempest Therapeutics, Inc. achieved positive results from phase 1b/2 study using TPST-1120 + Tecentriq + Avastin for the treatment of patients with 1st-line HCC; Significant improvements in both confirmed and unconfirmed responses. Updated results fr...

RHHVF - TG Therapeutics: The Cloud Over Briumvi

2024-04-17 10:24:12 ET Summary TG Therapeutics shares are down 60% from their 52-week high after rival MS therapy Ocrevus achieved non-inferiority as a subcutaneously injected therapy. Initial sales of TG Therapeutics' anti-CD20 MS treatment Briumvi were solid, generating $92 mill...

RHHVF - International Wide-Moat Stocks On Sale - The April 2024 Heat Map

2024-04-17 01:50:40 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

RHHVF - VGK Vs. QQQ: How Europe's 'GRANOLAS' Could Outperform The US 'Magnificent 7'

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...

RHHVF - Novo Nordisk: The Moat Won't Last Forever

2024-04-09 11:30:10 ET Summary Today, we take a look at Novo Nordisk A/S, whose growth is being powered by Wegovy and Ozempic. The GLP-1 market is projected by some to grow to $100 billion by 2030 and Novo Nordisk is currently the preeminent player in this burgeoning space. Ho...

RHHVF - Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval

2024-03-31 09:25:35 ET Summary The positive CHMP opinion could mean possible European Approval; European Commission expected to decide upon approval for this in the next few months. Phase 3 NORSE EIGHT study underway using ONS-5010 for the treatment of patients with Wet-AMD; Data ...

Previous 10 Next 10